Anthony Smith, MD
Pulmonary Disease · New York, NYNPI 1134201031
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $2,336 of the $3,491 with a category attached, or 66.9%. Chiesi USA, Inc. accounts for 69.5% of it on its own, with 11 other manufacturers making up the rest. 2025 is the largest year on record at $2,425, more than ten times the $135 reported in 2019.
Across 30 payments — averaging $116.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Chiesi USA, Inc.$2K
- Boehringer Ingelheim$250
- Mallinckrodt Hospital Products Inc.$242
- Insmed, Inc.$223
- GSK$88
- Actelion Pharmaceuticals US, Inc.$85
- plus $178 from 6 others
Across 42 payments — averaging $5439.96 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi US Services Inc.$168K
- Chiesi USA, Inc.$60K
What the payments were for
- Travel & lodging$2,33667%
- Food & beverage$1,06931%
- Education$852%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Chiesi USA, Inc. | 2 | $2,425 |
| Boehringer Ingelheim | 8 | $250 |
| Mallinckrodt Hospital Products Inc. | 2 | $242 |
| Insmed, Inc. | 2 | $223 |
| GSK | 4 | $88 |
| Actelion Pharmaceuticals US, Inc. | 1 | $85 |
| AstraZeneca | 4 | $69 |
| Philips North America LLC | 3 | $40 |
| Johnson & Johnson | 1 | $24 |
| Amgen | 1 | $18 |
| Pfizer | 1 | $14 |
| Lundbeck LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,491 in reported general payments places this provider in the 65th percentile of 1,115 pulmonary disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 113 | $74,965 |
| Breo ElliptaFluticasone/Vilanterol | 57 | $24,517 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 18 | $11,083 |
| SymbicortBudesonide/Formoterol Fumarate | 34 | $8,065 |
| Incruse ElliptaUmeclidinium Bromide | 22 | $7,745 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 40 | $6,987 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 12 | $5,460 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 113 | $4,180 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 33 | $4,111 |
| Advair DiskusFluticasone Propion/Salmeterol | 14 | $2,613 |
| Wixela InhubFluticasone Propion/Salmeterol | 33 | $2,590 |
| Montelukast Sodium | 23 | $483 |
| Fluticasone Propionate | 40 | $437 |
| Azelastine Hcl | 12 | $431 |
| Azithromycin | 41 | $345 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Anoro Ellipta | $88 | $112,687204 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $69 | $19,14852 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,115 pulmonary disease providers in New York.
Other pulmonary disease in New York
- Charles PowellNew York$654K
- Bisher AkilNew York$480K
- Sonali SethiNew York$388K
- Johnathan RaskinNew York$338K
- Monica KraftNew York$247K
- Jamie BessichNew York$226K
- Ronald CrystalNew York$213K
- Michael NiedermanNew York$176K
- Wilfredo TalaveraNew York$145K
- Josanna Rodriguez-LopezNew York$128K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.